Aprea Therapeutics, Inc. (APRE): Submission of Matters to a Vote of Security Holders
Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001781983 0001781983 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2026
How this was made
The 30-second read
Why it matters
The only potentially market-moving item is Proposal 3: stockholders approved an amendment authorizing a reverse stock split within a defined range, leaving final terms to the board.
Market read
Reverse-split authorization can drive microcap trading volatility, but the filing lacks the final ratio/timing, limiting immediate fundamental read-through.
What to watch
Traders should watch for subsequent board action specifying the exact split ratio and effective date, plus any concurrent financing or listing-compliance disclosures that would change the risk calculus.
Background
This is an SEC 8-K reporting the outcomes of Aprea Therapeutics’ June 16, 2026 annual meeting proposals, including director elections, auditor ratification, and advisory votes on executive compensation.
Ticker impact
Aprea Therapeutics’ June 16, 2026 annual meeting results include stockholder approval to authorize a reverse stock split within a 1-for-3 to 1-for-8 range.
Likely short-term volatility around reverse-split expectations; direction uncertain until the board sets the ratio and effective date.
The filing confirms approval of the authorization, not the final split terms; traders typically reprice on implementation details rather than authorization alone.
Market effects
For small-cap biotech, reverse-split authorizations can influence peer sentiment around capital-market access and listing compliance risk.
Primarily US small-cap/Nasdaq sentiment; limited spillover beyond microcap biotech complex.
Minimal; corporate-action mechanics are company-specific.
Counterpoint
Authorization does not guarantee the company will execute the reverse split soon, and the board may choose a less aggressive ratio or delay implementation.
Key entities
- companyAprea Therapeutics, Inc.
Reported annual meeting vote results, including authorization for a reverse stock split (1-for-3 to 1-for-8).
- auditorEisnerAmper LLP
Ratified as independent registered public accounting firm for fiscal year 2026.
